Zeping Zuo
Sichuan University
17 Papers
24 Citations
Zeping Zuo is an academic researcher from Sichuan University. The author has contributed to research in topics: Chemistry & Medicine. The author has an hindex of 5, co-authored 12 publications.
Chat about Author
Papers
DHODH and cancer: promising prospects to be explored
Yue Zhou,Lei Tao,Xia Zhou,Zeping Zuo,Jin Gong,Xiaocong Liu,Yang Zhou,Chunqi Liu,Na Sang,Huan Liu,Jiao Zou,Kun Gou,Xiaowei Yang,Yinglan Zhao +13 more
TL;DR: In this paper, the authors mainly unravel the biological function of DHODH in tumor progression, including its crucial role in de novo pyrimidine synthesis and mitochondrial respiratory chain in cancer cells.
Uric Acid Induces Cognitive Dysfunction through Hippocampal Inflammation in Rodents and Humans.
Xiaoni Shao,Wenjie Lu,Fabao Gao,Dandan Li,Jing Hu,Yan Li,Zeping Zuo,Hui Jie,Yinglan Zhao,Xiaobo Cen +9 more
TL;DR: It is shown that a high-UA diet triggers the expression of proinflammatory cytokines, activates the Toll-like receptor 4 (TLR4)/nuclear factor (NF)-κB pathway, and increases gliosis in the hippocampus of Wistar rats, suggesting that UA can cause hippocampal inflammation via the TLR4/NF-κB pathways, resulting in cognitive dysfunction.
The synthesis, structure-toxicity relationship of cisplatin derivatives for the mechanism research of cisplatin-induced nephrotoxicity.
TL;DR: The potency of biotin-pyridine conjugated derivative 3 met the requirement for target identification, and the preliminary chemical proteomics results suggested that it is a promising tool for further target identification of cisplatin-induced nephrotoxicity.
14
A novel series of human dihydroorotate dehydrogenase inhibitors discovered by in vitro screening: inhibition activity and crystallographic binding mode.
TL;DR: The high‐resolution crystal structures of human DHODH complexed with various agents reveal the details of their interactions, and comparisons with the binding modes of teriflunomide and brequinar provide insights that may facilitate the development of new inhibitors targeting humanDHODH.
9
Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51
Lei Tao,Yuee Zhou,Xiangyu Pan,Yuan Luo,Jia-Hui Qiu,Xia Zhou,Zhiqian Chen,Yan Li,Lian Xu,Yangli Zhou,Zeping Zuo,Chunqi Liu,Liang Wang,Xiaocong Liu,Xinyu Tian,Na Su,Yu Zhang,Kun Gou,Na Sang,Huan Liu,Jiao Zou,Yuzhou Xiao,Xincheng Zhong,Jing Xu,Xinyu Yang,Kai Xiao,Yanyang Liu,Sheng-Hsiung Yang,Yong Peng,Junhong Han,Xiaobo Cen,Yinglan Zhao +31 more
TL;DR: It is demonstrated that lysine-specific demethylase 1 (LSD1) is an important regulator for OC and combination with LSD1 inhibitor could greatly expand the utility of PARPi to patients with HR-proficient tumor, warranting assessment in human clinical trials.
8